What is the recommended intensive insulin therapy regimen for children with type 1 diabetes?

Intensive Insulin Therapy for Children with Type 1 Diabetes

Children with type 1 diabetes should be treated with a basal-bolus insulin regimen using either multiple daily injections (MDI) of 3-4 injections per day or continuous subcutaneous insulin infusion (CSII/insulin pump), with insulin analogs preferred over human insulin to reduce hypoglycemia risk. 1, 2

Core Insulin Regimen Components

The intensive insulin therapy regimen consists of three essential elements:

• Basal insulin: Long-acting insulin analog (glargine, detemir, or degludec) given once or twice daily, OR continuous delivery via insulin pump
• Prandial/bolus insulin: Rapid-acting insulin analog (lispro, aspart, or glulisine) given before each meal
• Correction insulin: Additional rapid-acting insulin to correct elevated blood glucose levels

3, 2

Starting Insulin Doses

Initial total daily insulin dose is weight-based:

• Newly diagnosed children: 0.5-1.0 units/kg/day 3, 4
• Younger/prepubertal children: Lower end of range (0.5 units/kg/day)
• Pubertal adolescents: May require up to 1.5 units/kg/day due to growth hormone and sex hormone effects 3
• Infants and toddlers: May require diluted insulin for precise 1-unit increment dosing 3

The dose is typically split approximately 50% basal and 50% bolus insulin, though this requires individualization based on blood glucose patterns.

MDI vs. Insulin Pump: Equivalent Outcomes

Both MDI and CSII are equally effective - a systematic review and meta-analysis found no systematic differences in A1C or severe hypoglycemia rates between the two approaches in children and adults 1. The choice should be based on patient/family preference, lifestyle needs, and resources rather than expected glycemic superiority. However, sensor-augmented pump therapy with threshold suspend features can reduce nocturnal hypoglycemia without increasing A1C 1, 4.

Why Insulin Analogs Over Human Insulin

Insulin analogs are strongly preferred because they are associated with less hypoglycemia while achieving equivalent A1C lowering compared to human insulins 1, 2. This is particularly critical in children where hypoglycemia poses neurodevelopmental risks, especially in those under 6 years old 3.

Essential Education Components

Children and families must receive education on:

• Carbohydrate counting and matching prandial insulin doses to carbohydrate intake 1, 4
• Adjusting insulin for premeal blood glucose levels
• Modifying doses for anticipated physical activity
• For advanced users: adjusting for fat and protein content 1

Age-Specific Glycemic Targets

The guidelines provide clear A1C targets that balance glycemic control against hypoglycemia risk 3:

• Children <6 years: A1C 7.5-8.5% (high vulnerability to hypoglycemia and neurodevelopmental concerns)
• Children 6-12 years: A1C <8% (most amenable to intensive control)
• Adolescents 13-19 years: A1C <7.5% (ideal 7% if achievable without excessive hypoglycemia)

Blood glucose targets vary by age:

• <6 years: Premeal 100-180 mg/dL, bedtime 110-200 mg/dL
• 6-12 years: Premeal 90-180 mg/dL, bedtime 100-180 mg/dL
• 13-19 years: Premeal 90-130 mg/dL, bedtime 90-150 mg/dL

3

Common Pitfalls to Avoid

Do not use twice-daily insulin regimens - these cannot maintain A1C within target range for 50-70% of pediatric patients, especially after the honeymoon period 3. Recent evidence shows that avoiding twice-daily regimens from diagnosis improves outcomes, with one study demonstrating improved mean A1C (58.2 vs 63.7 mmol/mol) and 40% vs 11% achieving target A1C when twice-daily regimens were avoided 5.

Do not mix glargine with other insulins - it must be given as a separate injection 3.

Avoid intramuscular injections - use the shortest needles (4mm pen needles) to prevent IM injection, which can cause severe hypoglycemia, particularly with long-acting insulins 6.

The Honeymoon Phase

During the honeymoon phase (weeks to months after diagnosis), insulin requirements may drop well below 0.5 units/kg/day. Continue minimal insulin therapy during this period rather than stopping completely, as beta-cell destruction continues despite temporary improved function 3.

Monitoring Requirements

Blood glucose monitoring or continuous glucose monitoring (CGM) is essential and non-negotiable for safe intensive insulin therapy 3. CGM should be offered to all children on intensive insulin regimens who can use it safely 2, 7.

Evidence Strength

The recommendation for intensive insulin therapy is based on the landmark DCCT trial, which demonstrated 50% reductions in microvascular complications with intensive therapy (A1C ~7%) compared to conventional treatment 1, 2. While the DCCT showed increased severe hypoglycemia with intensive therapy using human insulins (62 vs 19 episodes per 100 patient-years), modern insulin analogs have significantly reduced this risk while maintaining glycemic benefits 1, 2.